Trial Profile
A Phase II Clinical Study of Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Patients With Advanced Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Bexarotene (Primary) ; Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 12 Nov 2014 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 02 Aug 2013 Planned end date changed from 1 Jul 2013 to 1 Jul 2014 as reported by ClinicalTrials.gov.
- 08 Jan 2013 Planned end date changed from 1 Dec 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov.